Sectors
JBIO
Jade Biosciences, Inc.
20.94
1 x 20.61
1 x 20.86
bid
ask
+
0.10
0.48%
02:06 PM
timesize
| Ytd | 35.71% | |
| 1y | 165.06% |
20.35
day range
21.09
6.91
52 week range
28.00
| Open | 20.65 | Prev Close | 20.84 | Low | 20.35 | High | 21.09 | Mkt Cap | 1.33B |
| Vol | 276.68K | Avg Vol | 1.12M | EPS | -1.07 | P/E | N/A | Forward P/E | -7.83 |
| Beta | 1.49 | Short Ratio | 11.10 | Inst. Own | 115.93% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 21.33 | 200-d Avg | 17.76 | 1yr Est | 50.13 |
| Income Statement | |||
| Operating Expenses | 58.92M | ||
| Research and Development Expense | 50.07M | ||
| Selling, General and Administrative Expense | 8.85M | ||
| Operating Income | -58.92M | ||
| Income Tax Expense | 15.00K | ||
| Net Income | -55.76M | ||
| Net Income Common Stock | -55.76M | ||
| Net Income Common Stock (USD) | -55.76M | ||
| Consolidated Income | -55.76M | ||
| Earnings per Basic Share | -0.76 | ||
| Earnings per Basic Share (USD) | -0.76 | ||
| Earnings per Diluted Share | -0.76 | ||
| Earning Before Interest & Taxes (EBIT) | -55.75M | ||
| Earning Before Interest & Taxes (USD) | -55.75M | ||
| Weighted Average Shares | 61.05M | ||
| Weighted Average Shares Diluted | 61.05M | ||
| Balance Sheet | |||
| Cash and Equivalents | 107.25M | ||
| Cash and Equivalents (USD) | 107.25M | ||
| Investments | 353.96M | ||
| Investments Current | 353.96M | ||
| Current Assets | 471.25M | ||
| Property, Plant & Equipment Net | 793.00K | ||
| Total Assets | 472.11M | ||
| Total Debt | 628.00K | ||
| Current Liabilities | 31.57M | ||
| Debt Non-Current | 628.00K | ||
| Total Liabilities | 32.20M | ||
| Accumulated Retained Earnings (Deficit) | -270.52M | ||
| Accumulated Other Comprehensive Income | -660.00K | ||
| Shareholders Equity | 439.92M | ||
| Shareholders Equity (USD) | 439.92M | ||
| Assets Non-Current | 862.00K | ||
| Total Debt (USD) | 628.00K | ||
| Liabilities Non-Current | 628.00K | ||
| Trade and Non-Trade Payables | 6.58M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 34.00K | ||
| Net Cash Flow from Financing | 193.52M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 52.17M | ||
| Issuance (Purchase) of Equity Shares | 193.52M | ||
| Net Cash Flow from Investing | -97.63M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -97.63M | ||
| Net Cash Flow from Operations | -43.66M | ||
| Effect of Exchange Rate Changes on Cash | -70.00K | ||
| Share Based Compensation | 13.61M | ||